ClinicalTrials.gg
CompletedNCT05902598Updated Feb 27, 2026Results posted

A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

A Phase 3 interventional study of Plozasiran and Placebon in Familial Chylomicronemia Syndrome, sponsored by Visirna Therapeutics HK Limited. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Visirna Therapeutics HK Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, double-blinded, placebo controlled, two periods phase 3 clinical study. The primary objective of the study was to evaluate the efficacy and safety of Plozasiran injection in Chinese adults with familial chylomicronemia syndrome (FCS). A total of 37 participants were enrolled in the study. The duration of the study randomized period was approximately 112 weeks, including a screening period of up to 8 weeks and a treatment period of up to 104 weeks. Participants who completed the randomized period will continue in a 1-year open-label extension period where all participants will receive Plozasiran.

02

Conditions studied

  • Familial Chylomicronemia Syndrome
03

In context

Lead sponsor

Visirna Therapeutics HK Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or nonpregnant (who do not plan to become pregnant), nonlactating females ≥18 years of age
  • Fasting triglycerides (TG) ≥10 mmol/L (\~880 mg/dL) at screening, that is to standard lipid lowering therapy (sample drawn after at least the minimum time on stable lipid-lowering regimen described in protocol). Two repeat tests are allowed to qualify.
  • A diagnosis of FCS
  • Willing to follow dietary counseling as per PI judgment based on local standard of care, consistent with an intake of ≤20 g of fat per day during the study
  • If on medications for management of type 2 diabetes, or other medications specified in protocol, the dosing regimen must be stable before collection of qualified lipid parameter at screening.
  • Participants with a medical history of clinical atherosclerotic cardiovascular disease (ASCVD) or those with elevated 10-year ASCVD risk (eg, ≥7.5% per American Heart Association / American College of Cardiology risk calculator) must be on appropriate lipid-lowering therapy as per local standard of care (ie, including moderate to high intensity statin, as indicated) prior to collection of qualifying TG levels.
  • Participants of must agree to use a highly effective form of in addition to a male condom, during the study and for at least 24 weeks after the last dose of product (IP). Women of childbearing potential on a hormonal contraceptive must be stable on the medication for ≥1 menstrual cycles prior to Day 1. Men must not donate sperm during the study and for at least 24 weeks after the last dose of IP.

Exclusion criteria

Exclusion Criteria:

  • Current use or use within the last 365 days from Day 1 of any hepatocyte-targeted siRNA or antisense oligonucleotide molecule
  • Diabetes mellitus with any of the following:

    1. Newly diagnosed within 12 weeks of screening
    2. ≥9.0% at screening
  • Active pancreatitis within 12 weeks before Day 1
  • History of acute coronary syndrome event within 24 weeks of Day 1

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Plozasiran 25 mg

    Plozasiran 25 mg administered every 3 months for 12 months (randomized period), followed by an open-label period of 12 months

    Drug: Plozasiran

  • Experimental
    Plozasiran 50 mg

    Plozasiran 50 mg administered every 3 months for 12 months (randomized period), followed by an open-label period of 12 months

    Drug: Plozasiran

  • Placebo comparator
    Placebo

    Matching placebo administered every 3 months for 12 months

    Drug: Placebon

Interventions

  • Subcutaneous injection

    Also known as: ARO-APOC3, SAR449124, VSA001

  • DrugPlacebon

    Subcutaneous injection

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10

    Blood samples for lipid parameters were collected at the specified time points. Fasting serum TG at Month 10 was defined as geometric mean of 2 measurements taken during Month 10, or the other non-missing measurement if any one of the two measurements was missing during Month 10. Analysis was performed on the basis of the handling strategy for intercurrent events, missing fasting serum was imputed mainly based on the Pattern Mixture Models (PMM). Descriptive statistics were calculated based on non-imputed data.

    Time frame: Baseline to Month 10

Secondary outcomes

  1. Percent Change From Baseline in Fasting Serum TG at Months 10 and 12 (Averaged)

    Blood samples for lipid parameters were collected at the specified time points. Fasting serum TG at Month 10 and Month 12 was defined as the geometric mean of the measurements in Month 10 and Month 12 or the non-missing measurement in the other month if measurement in any one of the two months was missing. Analysis was performed on the basis of the handling strategy for intercurrent events, missing fasting serum TG was imputed mainly based on the PMM. Descriptive statistics were calculated based on non-imputed data.

    Time frame: Baseline to Months 10 and 12 (averaged)

  2. Percent Change From Baseline in Fasting Serum Apolipoprotein C3 (APOC3) at Month 10

    Blood samples for lipid parameters were collected at the specified time points. Baseline of fasting serum APOC 3 was defined as the last non-missing value prior to or on the first dosing date. Analysis was performed on the basis of the handling strategy for intercurrent events, missing values were imputed using the PMM. Descriptive statistics were calculated based on non-imputed data.

    Time frame: Baseline to Month 10

  3. Percent Change From Baseline in Fasting Serum APOC3 at Month 12

    Blood samples for lipid parameters were collected at the specified time points. Baseline of fasting serum APOC 3 was defined as the last non-missing value prior to or on the first dosing date. Analysis was performed on the basis of the handling strategy for intercurrent events, missing values were imputed using the PMM. Descriptive statistics were calculated based on non-imputed data.

    Time frame: Baseline to Month 12

  4. Percent Change From Baseline in Fasting Serum Non-high Density Lipoprotein Cholesterol (Non-HDL-C) and High Density Lipoprotein Cholesterol (HDL-C) at Month 10

    Blood samples for lipid parameters were collected at the specified time points. Baseline was defined as the last non-missing value prior to or on the first dosing date.

    Time frame: Baseline to Month 10

  5. Percent Change From Baseline in Fasting Serum TG, Non-HDL-C, and HDL-C at Month 12

    Blood samples for lipid parameters were collected at the specified time points. Non-HDL-C and HDL-C baseline was defined as the last non-missing value prior to or on the first dosing date.

    Time frame: Baseline to Month 12

  6. Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 10

    Blood samples for lipid parameters were collected at the specified time points.

    Time frame: 10 Month

  7. Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 12

    Blood samples for lipid parameters were collected at the specified time points.

    Time frame: 12 Month

  8. Change From Baseline at Each Scheduled Assessment in Fasting Serum TG up to Month 12

    Blood samples for lipid parameters were collected at the specified time points.

    Time frame: From baseline up to Month 12, at Months 1,2,3,4,5,6,7,8,9,10,11 and 12

  9. Percent Change From Baseline at Each Scheduled Assessment in Fasting Serum TG up to Month 12

    Blood samples for lipid parameters were collected at the specified time points.

    Time frame: From baseline up to Month 12, at Months 1,2,3,4,5,6,7,8,9,10,11 and 12

  10. Number of Participants With Positively Adjudicated Events of Acute Pancreatitis

    Any AEs and SAEs reported by the investigator during the study that were consistent with acute pancreatitis events were adjudicated by the blinded Data Safety Committee based on the Atlanta Classification for Acute Pancreatitis 2013 for fulfillment of any 2 of the following 3 criteria: 1. Abdominal pain consistent with symptoms of acute pancreatitis (acute episodes of persistent, severe upper abdominal pain often radiating to the back) 2. Serum lipase activity (or amylase activity) ≥3 × upper limit of normal (ULN) 3. Characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) or transabdominal ultrasonography

    Time frame: From first administration of study treatment (Day 1) through Month 12.

07

Results

Posted Feb 27, 2026

Participant flow

A total of 63 participants were screened from 10-July-2023 to 19-Jan-2024, of which 26 participants were screen failures mainly due to selection criteria not met.

Participant flow — Overall Study
MilestonePlozasiran 25 mgPlozasiran 50 mgPlacebo
Started121213
Completed101111
Not completed212
Withdrew: Withdrawal by subject100
Withdrew: Lost to follow-up010
Withdrew: Poor compliance and unable to receive treatment and attend visits as scheduled100
Withdrew: Other reason001
Withdrew: Subjects were transfered to the extension phase after unblinding due to an acute pancreatitis event001

Outcome measures

PrimaryPercent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10

Blood samples for lipid parameters were collected at the specified time points. Fasting serum TG at Month 10 was defined as geometric mean of 2 measurements taken during Month 10, or the other non-missing measurement if any one of the two measurements was missing during Month 10. Analysis was performed on the basis of the handling strategy for intercurrent events, missing fasting serum was imputed mainly based on the Pattern Mixture Models (PMM). Descriptive statistics were calculated based on non-imputed data.

Time frame:
Baseline to Month 10
Reported as:
Median · Percent change
Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10
Percent changePlozasiran 25 mgPlozasiran 50 mgPlacebo
Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10-85.7 (-97.3 to -43.9)-89.5 (-94.7 to -18.1)38.8 (-56.2 to 136.7)
Statistical analysis
  • Plozasiran 25 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0022 (Adjusted P value referred to the P value adjusted for multiplicity using the Holm method for comparison between two dose groups. Threshold for significance at two-sided 0.05 level.) · Median difference (final values): -101.7 · 95% CI -167.8 to -35.5The Hodges-Lehmann method was used, the estimator represents the median of all possible paired differences between the two groups, rather than the direct subtraction of their individual medians.
  • Plozasiran 50 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0022 (Adjusted P value referred to the P value adjusted for multiplicity using the Holm method for comparison between two dose groups. Threshold for significance at two-sided 0.05 level.) · Median difference (final values): -103.2 · 95% CI -168.9 to -37.5The Hodges-Lehmann method was used, the estimator represents the median of all possible paired differences between the two groups, rather than the direct subtraction of their individual medians.
SecondaryPercent Change From Baseline in Fasting Serum TG at Months 10 and 12 (Averaged)

Blood samples for lipid parameters were collected at the specified time points. Fasting serum TG at Month 10 and Month 12 was defined as the geometric mean of the measurements in Month 10 and Month 12 or the non-missing measurement in the other month if measurement in any one of the two months was missing. Analysis was performed on the basis of the handling strategy for intercurrent events, missing fasting serum TG was imputed mainly based on the PMM. Descriptive statistics were calculated based on non-imputed data.

Time frame:
Baseline to Months 10 and 12 (averaged)
Reported as:
Median · Percent change
Percent Change From Baseline in Fasting Serum TG at Months 10 and 12 (Averaged)
Percent changePlozasiran 25 mgPlozasiran 50 mgPlacebo
Percent Change From Baseline in Fasting Serum TG at Months 10 and 12 (Averaged)-82.1 (-96.8 to -41.5)-86.6 (-93.3 to -26.1)49.5 (-56.4 to 457.7)
Statistical analysis
  • Plozasiran 25 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0055 (Adjusted P value referred to the P value adjusted for multiplicity using the Holm method for comparison between two dose groups. Threshold for significance at two-sided 0.05 level.) · Median difference (final values): -80.3 · 95% CI -160.5 to -0.0The Hodges-Lehmann method was used, the estimator represents the median of all possible paired differences between the two groups, rather than the direct subtraction of their individual medians.
  • Plozasiran 50 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0051 (Adjusted P value referred to the P value adjusted for multiplicity using the Holm method for comparison between two dose groups. Threshold for significance at two-sided 0.05 level.) · Median difference (final values): -85.0 · 95% CI -166.4 to -3.6The Hodges-Lehmann method was used, the estimator represents the median of all possible paired differences between the two groups, rather than the direct subtraction of their individual medians.
SecondaryPercent Change From Baseline in Fasting Serum Apolipoprotein C3 (APOC3) at Month 10

Blood samples for lipid parameters were collected at the specified time points. Baseline of fasting serum APOC 3 was defined as the last non-missing value prior to or on the first dosing date. Analysis was performed on the basis of the handling strategy for intercurrent events, missing values were imputed using the PMM. Descriptive statistics were calculated based on non-imputed data.

Time frame:
Baseline to Month 10
Reported as:
Median · Percent change
Percent Change From Baseline in Fasting Serum Apolipoprotein C3 (APOC3) at Month 10
Percent changePlozasiran 25 mgPlozasiran 50 mgPlacebo
Percent Change From Baseline in Fasting Serum Apolipoprotein C3 (APOC3) at Month 10-92.55 (-97.57 to -85.70)-91.83 (-99.78 to -84.19)19.91 (-28.35 to 79.48)
Statistical analysis
  • Plozasiran 25 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0008 (Adjusted P value referred to the P value adjusted for multiplicity using the Holm method for comparison between two dose groups. Threshold for significance at two-sided 0.05 level.) · Median difference (final values): -112.73 · 95% CI -140.47 to -85.00The Hodges-Lehmann method was used, the estimator represents the median of all possible paired differences between the two groups, rather than the direct subtraction of their individual medians.
  • Plozasiran 50 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0004 (Adjusted P value referred to the P value adjusted for multiplicity using the Holm method for comparison between two dose groups. Threshold for significance at two-sided 0.05 level.) · Median difference (final values): -115.25 · 95% CI -141.89 to -88.61The Hodges-Lehmann method was used, the estimator represents the median of all possible paired differences between the two groups, rather than the direct subtraction of their individual medians.
SecondaryPercent Change From Baseline in Fasting Serum APOC3 at Month 12

Blood samples for lipid parameters were collected at the specified time points. Baseline of fasting serum APOC 3 was defined as the last non-missing value prior to or on the first dosing date. Analysis was performed on the basis of the handling strategy for intercurrent events, missing values were imputed using the PMM. Descriptive statistics were calculated based on non-imputed data.

Time frame:
Baseline to Month 12
Reported as:
Median · Percent change
Percent Change From Baseline in Fasting Serum APOC3 at Month 12
Percent changePlozasiran 25 mgPlozasiran 50 mgPlacebo
Percent Change From Baseline in Fasting Serum APOC3 at Month 12-83.98 (-93.41 to -13.93)-88.16 (-94.83 to -71.13)22.56 (-29.38 to 334.31)
Statistical analysis
  • Plozasiran 25 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0016 (Adjusted P value referred to the P value adjusted for multiplicity using the Holm method for comparison between two dose groups. Threshold for significance at two-sided 0.05 level.) · Median difference (final values): -105.36 · 95% CI -164.69 to -46.03The Hodges-Lehmann method was used, the estimator represents the median of all possible paired differences between the two groups, rather than the direct subtraction of their individual medians.
  • Plozasiran 50 mg vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0008 (Adjusted P value referred to the P value adjusted for multiplicity using the Holm method for comparison between two dose groups. Threshold for significance at two-sided 0.05 level.) · Median difference (final values): -114.36 · 95% CI -175.31 to -53.40The Hodges-Lehmann method was used, the estimator represents the median of all possible paired differences between the two groups, rather than the direct subtraction of their individual medians.
SecondaryPercent Change From Baseline in Fasting Serum Non-high Density Lipoprotein Cholesterol (Non-HDL-C) and High Density Lipoprotein Cholesterol (HDL-C) at Month 10

Blood samples for lipid parameters were collected at the specified time points. Baseline was defined as the last non-missing value prior to or on the first dosing date.

Time frame:
Baseline to Month 10
Reported as:
Median · Percent change
Percent Change From Baseline in Fasting Serum Non-high Density Lipoprotein Cholesterol (Non-HDL-C) and High Density Lipoprotein Cholesterol (HDL-C) at Month 10
Percent changePlozasiran 25 mgPlozasiran 50 mgPlacebo
Percent change in fasting serum Non-HDL-C-37.76 (-63.8 to 37.5)-17.83 (-58.0 to 360.4)40.34 (-3.1 to 218.2)
Percent change in fasting serum HDL-C71.62 (0.0 to 166.1)86.84 (47.7 to 190.2)-3.51 (-43.1 to 14.3)
SecondaryPercent Change From Baseline in Fasting Serum TG, Non-HDL-C, and HDL-C at Month 12

Blood samples for lipid parameters were collected at the specified time points. Non-HDL-C and HDL-C baseline was defined as the last non-missing value prior to or on the first dosing date.

Time frame:
Baseline to Month 12
Reported as:
Median · Percent change
Percent Change From Baseline in Fasting Serum TG, Non-HDL-C, and HDL-C at Month 12
Percent changePlozasiran 25 mgPlozasiran 50 mgPlacebo
Percent change in fasting serum TG-71.56 (-96.2 to 59.1)-79.22 (-92.5 to -13.4)79.41 (-62.1 to 1213.9)
Percent change in fasting serum Non-HDL-C-7.21 (-48.6 to 63.3)-29.22 (-61.7 to 315.4)40.67 (-2.3 to 96.7)
Percent change in fasting serum HDL-C51.32 (-23.2 to 130.4)65.33 (21.5 to 178.4)-11.86 (-93.3 to 40.4)
SecondaryPercentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 10

Blood samples for lipid parameters were collected at the specified time points.

Time frame:
10 Month
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 10
Percentage of participantsPlozasiran 25 mgPlozasiran 50 mgPlacebo
Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 1090.081.89.1
SecondaryPercentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 12

Blood samples for lipid parameters were collected at the specified time points.

Time frame:
12 Month
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 12
Percentage of participantsPlozasiran 25 mgPlozasiran 50 mgPlacebo
Percentage of Participants Achieving Fasting Serum TG of <500 mg/dL at Month 1260.072.718.2
SecondaryChange From Baseline at Each Scheduled Assessment in Fasting Serum TG up to Month 12

Blood samples for lipid parameters were collected at the specified time points.

Time frame:
From baseline up to Month 12, at Months 1,2,3,4,5,6,7,8,9,10,11 and 12
Reported as:
Median · mmol/L
Change From Baseline at Each Scheduled Assessment in Fasting Serum TG up to Month 12
mmol/LPlozasiran 25 mgPlozasiran 50 mgPlacebo
Change from baseline in fasting serum TG at month 1-12.716 (-33.29 to -4.40)-13.610 (-24.48 to -7.87)0.568 (-15.04 to 10.30)
Change from baseline in fasting serum TG at month 2-12.029 (-34.49 to -6.11)-10.892 (-18.72 to 0.15)-3.079 (-16.56 to 59.98)
Change from baseline in fasting serum TG at month 3-9.789 (-35.00 to -2.65)-12.248 (-27.59 to -0.49)-4.617 (-14.28 to 12.60)
Change from baseline in fasting serum TG at month 4-11.849 (-35.81 to -6.55)-15.933 (-27.27 to -7.69)0.372 (-7.28 to 21.88)
Change from baseline in fasting serum TG at month 5-11.804 (-34.98 to 0.62)-11.967 (-20.50 to -4.98)-2.778 (-9.19 to 25.40)
Change from baseline in fasting serum TG at month 6-11.434 (-34.96 to 8.34)-12.921 (-29.17 to -7.74)-1.008 (-9.81 to 54.54)
Change from baseline in fasting serum TG at month 7-14.784 (-35.59 to -7.50)-14.279 (-33.73 to -1.95)-0.809 (-8.87 to 10.15)
Change from baseline in fasting serum TG at month 8-10.856 (-35.56 to -1.49)-8.815 (-31.97 to 32.42)-2.684 (-7.73 to 23.63)
Change from baseline in fasting serum TG at month 9-9.684 (-34.83 to -4.30)-11.134 (-26.37 to 8.07)-2.325 (-7.86 to 24.53)
Change from baseline in fasting serum TG at month 10-12.124 (-35.57 to -7.09)-11.667 (-23.97 to -5.57)3.794 (-8.40 to 16.34)
Change from baseline in fasting serum TG at month 11-10.674 (-35.22 to 14.64)-14.040 (-25.62 to -6.41)-0.453 (-7.87 to 12.34)
Change from baseline in fasting serum TG at month 12-10.208 (-35.19 to 12.17)-13.750 (-35.50 to -1.37)10.627 (-12.76 to 102.27)
SecondaryPercent Change From Baseline at Each Scheduled Assessment in Fasting Serum TG up to Month 12

Blood samples for lipid parameters were collected at the specified time points.

Time frame:
From baseline up to Month 12, at Months 1,2,3,4,5,6,7,8,9,10,11 and 12
Reported as:
Median · Percent change
Percent Change From Baseline at Each Scheduled Assessment in Fasting Serum TG up to Month 12
Percent changePlozasiran 25 mgPlozasiran 50 mgPlacebo
Percent change from baseline in fasting serum TG at month 1-87.17 (-94.1 to -37.0)-91.71 (-96.8 to -42.6)3.86 (-73.4 to 55.1)
Percent change from baseline in fasting serum TG at month 2-87.31 (-94.3 to -58.3)-81.86 (-95.2 to 0.3)-30.22 (-80.8 to 377.3)
Percent change from baseline in fasting serum TG at month 3-84.49 (-95.7 to -10.1)-77.24 (-96.8 to -2.3)-47.54 (-71.6 to 129.0)
Percent change from baseline in fasting serum TG at month 4-91.24 (-97.9 to -25.3)-87.47 (-95.5 to -60.9)-4.74 (-63.8 to 126.8)
Percent change from baseline in fasting serum TG at month 5-89.10 (-95.7 to 6.8)-88.04 (-94.5 to -25.8)-22.44 (-56.5 to 341.3)
Percent change from baseline in fasting serum TG at month 6-83.97 (-95.6 to 40.5)-75.58 (-96.6 to -56.3)-4.92 (-68.6 to 732.8)
Percent change from baseline in fasting serum TG at month 7-89.17 (-97.3 to -77.8)-87.41 (-96.3 to -14.4)-10.27 (-62.0 to 103.9)
Percent change from baseline in fasting serum TG at month 8-82.13 (-97.2 to -13.8)-70.49 (-92.9 to 128.1)-27.06 (-54.8 to 191.3)
Percent change from baseline in fasting serum TG at month 9-78.53 (-95.7 to -16.3)-82.26 (-93.8 to 40.2)-22.94 (-52.5 to 251.1)
Percent change from baseline in fasting serum TG at month 10-85.69 (-97.3 to -43.9)-89.46 (-94.7 to -18.1)38.84 (-56.2 to 136.7)
Percent change from baseline in fasting serum TG at month 11-75.00 (-96.3 to 71.1)-86.11 (-95.6 to -30.7)-3.67 (-55.0 to 133.6)
Percent change from baseline in fasting serum TG at month 12-71.56 (-96.2 to 59.1)-79.22 (-92.5 to -13.4)79.41 (-62.1 to 1213.9)
SecondaryNumber of Participants With Positively Adjudicated Events of Acute Pancreatitis

Any AEs and SAEs reported by the investigator during the study that were consistent with acute pancreatitis events were adjudicated by the blinded Data Safety Committee based on the Atlanta Classification for Acute Pancreatitis 2013 for fulfillment of any 2 of the following 3 criteria: 1. Abdominal pain consistent with symptoms of acute pancreatitis (acute episodes of persistent, severe upper abdominal pain often radiating to the back) 2. Serum lipase activity (or amylase activity) ≥3 × upper limit of normal (ULN) 3. Characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT) or magnetic resonance imaging (MRI) or transabdominal ultrasonography

Time frame:
From first administration of study treatment (Day 1) through Month 12.
Reported as:
Count of participants · Participants
Number of Participants With Positively Adjudicated Events of Acute Pancreatitis
ParticipantsPlozasiran 25 mgPlozasiran 50 mgPlacebo
Number of Participants With Positively Adjudicated Events of Acute Pancreatitis001

Adverse events

Collected over Adverse events (AE) data was collected from first dose of study treatment (Day 1) up to the Month 12. The data collection is ongoing for the Open-Label Extension period and the AE section will be updated after study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Plozasiran 25 mg0/12 (0%)1/12 (8.3%)11/12 (91.7%)
Plozasiran 50 mg0/12 (0%)0/12 (0%)10/12 (83.3%)
Placebo0/13 (0%)4/13 (30.8%)12/13 (92.3%)
Most frequent serious events
Most frequent serious events
EventPlozasiran 25 mgPlozasiran 50 mgPlacebo
Foot fractureInjury, poisoning and procedural complications1/120/120/13
Renal hydroceleRenal and urinary disorders1/120/120/13
UreterolithiasisRenal and urinary disorders1/120/120/13
Abdominal distensionGastrointestinal disorders0/120/121/13
Pancreatitis acuteGastrointestinal disorders0/120/121/13
Duodenal ulcerGastrointestinal disorders0/120/121/13
Cholecystitis acuteHepatobiliary disorders0/120/121/13
Most frequent other events
Showing 10 of 68
Most frequent other events
EventPlozasiran 25 mgPlozasiran 50 mgPlacebo
Hepatic function abnormalHepatobiliary disorders2/125/124/13
Upper respiratory tract infectionInfections and infestations4/122/121/13
Alanine aminotransferase increasedInvestigations3/123/121/13
Aspartate aminotransferase increasedInvestigations3/122/122/13
Influenza like illnessGeneral disorders3/123/122/13
Blood creatine phosphokinase increasedInvestigations0/120/123/13
Lipase increasedInvestigations0/122/121/13
Abdominal painGastrointestinal disorders2/121/120/13
DiarrhoeaGastrointestinal disorders2/121/120/13
ConstipationGastrointestinal disorders2/120/120/13

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Plozasiran 25 mgPlozasiran 50 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years12121337
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Plozasiran 25 mgPlozasiran 50 mgPlaceboTotal
Female4239
Male8101028
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Plozasiran 25 mgPlozasiran 50 mgPlaceboTotal
Race — Asian12121337
Race — Others0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Plozasiran 25 mgPlozasiran 50 mgPlaceboTotal
Ethnicity — Han11121235
Ethnicity — Others1012
Region of Enrollment
Region of Enrollment(Participants)Plozasiran 25 mgPlozasiran 50 mgPlaceboTotal
China12121337
Fasting serum TG (mg/dL)
Fasting serum TG (mg/dL)(mg/dL)Plozasiran 25 mgPlozasiran 50 mgPlaceboTotal
Mean1786.1 ± 894.041640.2 ± 856.151250.2 ± 444.261550.5 ± 766.64
08

Study locations

1 site
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Nov 2024, 16 months.

Results were first posted in Feb 2026, 1 year 3 months after primary completion. A results delay was requested in Nov 2025.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 15, 2023
StartActual
Jul 10, 2023
Primary completionActual
Nov 26, 2024
CompletionActual
Jan 9, 2026
Results delay requested
Nov 5, 2025
Results first posted
Feb 27, 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05902598
Lead sponsor
Visirna Therapeutics HK Limited
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Jul 10, 2023
Primary completion
Nov 26, 2024
Completion
Jan 9, 2026
Results posted
Feb 27, 2026
Last update
Feb 27, 2026

Study contacts

Dong YOU, MD., PhD.
study chair · Visirna Therapeutics HK Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plozasiran

Start the discussion